Most recent update: Friday, April 3, 2020 - 08:40

Bariatric News - Cookies & privacy policy

You are here

SCALE

Liraglutide adds non-diabetic overweight and obese

For people with prediabetes who are overweight or obese, adding 3.0mg of liraglutide for three years to a diet and exercise plan may lead to major health improvements, according to outcomes from the SCALE (Satiety and Clinical Adiposity - Liraglutide Evidence) trial, in a presentation, ‘OR36-1 Liraglutide 3.0 Mg Reduces Body Weight and Improves Cardiometabolic Risk Factors in Adults with Obesity or Overweight and Prediabetes: The Scale Obesity and Prediabetes Randomized, Double-Blind, Placebo-Controlled 3-Year Trial’, presented at ENDO 2016, the annual meeting of the Endocrine Society, in B

Liraglutide helps obese adults to lose weight effectively

Patients who received liraglutide 3.0 mg, combined with fewer calories and more physical activity, were more than twice as likely to achieve at least 5 to 10% of their start weight, compared to patients on placebo who made similar lifestyle changes. Patients who achieved that weight loss also showed improvements on a number of health markers, compared to those who lost less, and the patients on liraglutide showed greater improvement on measures of blood sugar control and blood pressure. The results were presented at ENDO 2015, the annual meeting of the Endocrine Society in San Diego.

SCALE: liraglutide demonstrates significantly greater weight loss

After 56 weeks of treatment, liraglutide 3mg, in combination with diet and exercise, provided significantly greater weight loss compared to placebo, according to the results from the SCALE Obesity and Pre-diabetes phase 3a trial.

The outcomes, presented at the 23rd Annual Congress of the American Association of Clinical Endocrinologists (AACE), showed that liraglutide patients reported more weight loss from baseline, 8 percent (8.4 kg) vs. 2.6 percent (2.8 kg) with placebo (p<0.0001).

Liraglutide 3mg

Subscribe to RSS - SCALE